A late stage clinical study of Aeterna Zentaris’ Zoptrex in women with locally advanced, recurrent or metastatic endometrial cancer has failed to meet its primary endpoint of demonstrating a statistically
A late stage clinical study of Aeterna Zentaris’ Zoptrex in women with locally advanced, recurrent or metastatic endometrial cancer has failed to meet its primary endpoint of demonstrating a statistically